<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04047680</url>
  </required_header>
  <id_info>
    <org_study_id>201509009RINB</org_study_id>
    <nct_id>NCT04047680</nct_id>
  </id_info>
  <brief_title>eGFR Evolution in HCV Patients Receiving SOF-based or SOF-free DAAs</brief_title>
  <official_title>Evolution of Estimated Glomerular Filtration Rate in Chronic Hepatitis C Patients Receiving Sofosbuvir-based or Sofosbuvir-free Direct Acting Antivirals</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Taiwan University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Taiwan University Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Data regarding the nephrotoxicity of sofosbuvir (SOF) remain controversial. The investigators&#xD;
      compared the changes of estimated glomerular filtration rate (eGFR) in patients with chronic&#xD;
      hepatitis C virus (HCV) infection receiving SOF-based or SOF-free direct acting antivirals&#xD;
      (DAAs).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Chronic hepatitis C virus (HCV) infection is a major health problem that affects 71 million&#xD;
      people worldwide. Patients with chronic HCV infection may present with various hepatic and&#xD;
      extrahepatic manifestations which lead to substantial morbidity and mortality. In contrast,&#xD;
      the long-term health outcome improves following successful HCV eradication by antiviral&#xD;
      therapies.&#xD;
&#xD;
      Owing to the excellent efficacy and safety as well as the short treatment duration, the use&#xD;
      of interferon (IFN)-free direct acting antivirals (DAAs) has become the standard-of-care for&#xD;
      managing HCV. Sofosbuvir (SOF) is a pyrimidine nucleotide analogue which acts as the HCV&#xD;
      ribonucleic acid (RNA) chain terminator by inhibiting HCV non-structural protein 5B (NS5B)&#xD;
      RNA-dependent RNA polymerase following intrahepatic activation to uridine triphosphate form.&#xD;
      Dephosphorylation results in the formation of inactive metabolite (GS-331007) that undergoes&#xD;
      extensive renal excretion. Clinically, SOF is administered once-daily with pangenotypic&#xD;
      potency, well tolerability and a high genetic barrier to drug resistance. Furthermore, SOF&#xD;
      can be used in combination with NS3/4A protease inhibitors (PIs), NS5A inhibitors, and/or&#xD;
      ribavirin (RBV) to achieve high rates of sustained virologic response (SVR). Therefore,&#xD;
      applying SOF-based DAAs for HCV is welcome to most treating physicians.&#xD;
&#xD;
      Following the widespread use of SOF-based DAAs for treating HCV in different populations, a&#xD;
      large-scale real-world HCV-TARGET study enrolling 1,789 patients indicated that patients with&#xD;
      a baseline eGFR â‰¤ 45 mL/min/1.73m2 were associated with a higher risk of worsening renal&#xD;
      function than those with a baseline eGFR &gt; 45 mL/min/1.73m2 following SOF-based DAAs.&#xD;
      Moreover, three retrospective studies showed that SOF-based DAAs negatively affected the&#xD;
      on-treatment and off-therapy eGFR. On the contrary, other studies showed that the use of&#xD;
      SOF-based DAAs did not worsen the eGFR. Because most studies were retrospective in nature&#xD;
      without protocol-defined time point for eGFR assessment or patient election, and did not&#xD;
      enroll patients receiving SOF-free DAAs as the controls, the investigators thus conducted a&#xD;
      prospective study to evaluate the evolution of eGFR in patients with chronic HCV infection&#xD;
      receiving SOF-based or SOF-free DAAs.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 2015</start_date>
  <completion_date type="Actual">June 2019</completion_date>
  <primary_completion_date type="Actual">December 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Slope differences of eGFR</measure>
    <time_frame>Baseline to off-therapy week 24</time_frame>
    <description>Slope differences of eGFR between SOF-based and SOF-free DAAs</description>
  </primary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">441</enrollment>
  <condition>Hepatitis C</condition>
  <condition>Renal Disease</condition>
  <condition>Viral Hepatitis C</condition>
  <arm_group>
    <arm_group_label>SOF-based DAAs</arm_group_label>
    <description>Patients receiving sofosbuvir (SOF)-based direct acting antiviral agents (DAAs) for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>SOF-free DAAs</arm_group_label>
    <description>Patients receiving sofosbuvir (SOF)-free direct acting antiviral agents (DAAs) for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir / Velpatasvir Oral Tablet</intervention_name>
    <description>Sofosbuvir/velpatasvir for 12 weeks</description>
    <arm_group_label>SOF-based DAAs</arm_group_label>
    <other_name>Epclusa</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir and Ledipasvir</intervention_name>
    <description>Sofosbuvir and ledipasvir for 12 weeks</description>
    <arm_group_label>SOF-based DAAs</arm_group_label>
    <other_name>Harvoni</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sofosbuvir Tablets</intervention_name>
    <description>Sofosbuvir plus ribavirin (RBV) or daclatasvir (DCV) for 12 weeks</description>
    <arm_group_label>SOF-based DAAs</arm_group_label>
    <other_name>Solvadi</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ombitasvir/paritaprevir/ritonavir</intervention_name>
    <description>Ombitasvir/paritaprevir/ritonavir for 12 weeks</description>
    <arm_group_label>SOF-free DAAs</arm_group_label>
    <other_name>Viekirax/exviera</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Elbasvir / Grazoprevir Oral Tablet</intervention_name>
    <description>Elbasvir/grazoprevir for 12 weeks</description>
    <arm_group_label>SOF-free DAAs</arm_group_label>
    <other_name>Zepatier</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glecaprevir and Pibrentasvir</intervention_name>
    <description>Glecaprevir/pibrentasvir for 12 weeks</description>
    <arm_group_label>SOF-free DAAs</arm_group_label>
    <other_name>Maviret</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Chronic hepatitis C virus-infected patients with compensated liver diseases and baseline&#xD;
        eGFR of 30 mL/min/1.73m2 or more, who received SOF-based or SOF-free DAAs for 12 weeks, and&#xD;
        who received off-therapy follow-up until week 24&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Chronic HCV patients receiving SOF-based or SOF-free DAAs for 12 weeks&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Decompensated cirrhosis (Child-Pugh B or C)&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) &lt; 30 mL/min/1.73m2&#xD;
&#xD;
          -  Active hepatocellular carcinoma (HCC)&#xD;
&#xD;
          -  Organ transplantation&#xD;
&#xD;
          -  Hepatitis B virus (HBV) co-infection&#xD;
&#xD;
          -  Human immunodeficiency virus (HIV) co-infection&#xD;
&#xD;
          -  Not received off-therapy follow-up till week 24&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jia-Horng Kao, PhD</last_name>
    <role>Study Director</role>
    <affiliation>National Taiwan University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Taiwan University Hospital, Yun-Lin Branch</name>
      <address>
        <city>Douliu</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>10002</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>August 2019</verification_date>
  <study_first_submitted>August 5, 2019</study_first_submitted>
  <study_first_submitted_qc>August 5, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 7, 2019</study_first_posted>
  <last_update_submitted>August 6, 2019</last_update_submitted>
  <last_update_submitted_qc>August 6, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">August 8, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Viral hepatitis C</keyword>
  <keyword>Glomerular filtration rate</keyword>
  <keyword>Direct acting antiviral agent</keyword>
  <keyword>Sofosbuvir</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hepatitis A</mesh_term>
    <mesh_term>Hepatitis C</mesh_term>
    <mesh_term>Hepatitis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ritonavir</mesh_term>
    <mesh_term>Sofosbuvir</mesh_term>
    <mesh_term>Ledipasvir, sofosbuvir drug combination</mesh_term>
    <mesh_term>Grazoprevir</mesh_term>
    <mesh_term>Ledipasvir</mesh_term>
    <mesh_term>Velpatasvir</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

